This is the authors' abstract. We don't add key points for this paper.
An efficient HMFCA production strategy was developed using a new whole-cell biocatalyst from Pseudomonas aeruginosa PC-1.
No takes yet. Share an insight, caveat, or question.
Pan et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: